Neurobo Pharmaceuticals Inc (NRBO) Financials

$1.89

$-0.09 (-4.55%)

As on 29-Jan-2025 09:30EDT

Market cap

$20 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1.3

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Operating Revenue	0.00	0.01	--	--	--	--
Cost of Revenue	0.01	0.01	0.03	0.07	0.07	0.02
Gross Profit	-0.01	--	-0.03	-0.07	-0.07	-0.02
Operating Expenses	28.88	15.89	11.42	15.30	29.72	20.18
Operating Profit (EBIT)	-28.89	-15.89	-19.63	-15.30	-29.72	-20.18
Other Income	--	--	--	--	--	--
Profit before Tax	-27.73	-12.47	-13.97	-15.28	-29.68	-21.31
Provision for Tax	-5.77	--	-7.85	-0.06	-0.09	1.12
Profit after Tax (Net Income)	-27.73	-12.47	-6.12	-15.22	-29.59	-22.43
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	-15.28	-29.68	-21.31

Liabilities ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Shareholder's Funds	12.95	16.69	21.75	14.60	7.20	12.29
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.08	0.14	0.71	0.05	0.07	0.09
Current Liabilities	9.11	5.96	11.78	2.16	3.70	2.08
Total Liabilities	31.26	22.78	33.53	16.80	10.97	14.47

Assets ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Non-Current Assets	0.21	0.27	0.00	0.22	0.29	0.35
Current Assets	21.94	22.51	33.53	16.58	10.68	14.12
Total Assets	31.26	22.78	33.53	16.80	10.97	14.47
Total Debt*	0.15	0.20	--	0.07	0.09	0.12
Net Current Assets	12.82	16.55	21.75	14.43	6.99	12.04

Cashflow ($ Mln)	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Cash From Operating Activities	--	-10.80	-11.71	-15.13	-10.76	-7.04
Cash Flow from Investing Activities	--	--	--	-0.59	0.07	-6.06
Cash from Financing Activities	--	-0.08	0.03	22.03	6.86	24.17
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Adjusted EPS ($)	--	--	--	--	--	--
Cash EPS ($)	--	--	--	--	--	--
Adjusted Book Value ($)	--	--	--	--	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	--	--	--	--	--
Free Cash Flow per Share ($)	--	--	--	--	--	--

Profitability Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
ROCE (%)	--	-64.55	-33.58	-138.60	-300.36	82.33
ROE (%)	-240.85	-64.89	-33.65	-139.65	-303.60	70.05
ROA (%)	-88.88	-44.29	-24.30	-109.64	-232.69	-131.32
EBIT Margin (%)	-640,975.00	-226,957.14	--	--	--	--
Net Margin (%)	-693,325.00	-178,142.86	--	--	--	--
Cash Profit Margin (%)	-36.49	--	--	--	--	--

Growth Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Revenue Growth (%)	--	--	--	--	--	--
EBIT Growth (%)	-24.16	-39.04	25.31	48.52	-47.28	11.53
Net Profit Growth (%)	-344.01	-103.92	59.83	48.56	-31.93	5.10
EPS Growth (%)	--	--	--	--	--	--
Book Value Growth (%)	--	--	--	--	--	--

Valuation Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Price / Earnings	--	--	--	--	--	--
Price / Book Value	1.32	--	--	--	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.43	1.40	2.93	1.07	0.34	0.72
Close Price ($)	3.17	3.70	5.74	292.80	1,260.00	2,100.00
High Price ($)	6.75	7.60	510.80	1,826.26	7,200.00	8,910.00
Low Price ($)	2.90	2.89	4.41	288.00	1,156.80	1,428.00
Market Cap ($ Cr)	20.33	--	--	--	--	--

Solvency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debt to Equity	--	0.01	--	0.00	0.01	0.01
Short term debt to equity ratio	0.01	0.01	--	0.00	0.01	0.00
Current Ratio	2.41	3.78	2.85	7.69	2.89	6.78
Quick Ratio	2.41	--	--	--	--	--
Interest Coverage	-329.15	--	-5.21	-1,092.71	-761.95	-917.09

Operating Efficiency Ratios	TTM	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14
Debtors to sales (%)	--	--	--	--	--	--
Asset Turnover	0.00	0.00	--	--	--	--
Receivable days	--	--	--	--	--	--
Inventory Days	--	--	--	--	--	--
Payable days	--	39,890.52	10,031.33	8,636.64	8,757.82	28,811.78
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.